Align Technology, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0162551016
USD
156.84
5.91 (3.92%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Align Technology, Inc. stock-summary
stock-summary
Align Technology, Inc.
Pharmaceuticals & Biotechnology
Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.
Company Coordinates stock-summary
Company Details
2820 Orchard Pkwy , SAN JOSE CA : 95134-2019
stock-summary
Tel: 1 408 47010001 408 4701150
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 160 Schemes (48.37%)

Foreign Institutions

Held by 403 Foreign Institutions (25.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Charles Larkin
Independent Chairman of the Board
Mr. Joseph Hogan
President, Chief Executive Officer, Director
Mr. Thomas Prescott
Director
Mr. Kevin Dallas
Independent Director
Mr. Joseph Lacob
Independent Director
Mr. George Morrow
Independent Director
Ms. Anne Myong
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,012 Million
(Quarterly Results - Jun 2025)
Net Profit:
125 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9,920 Million (Small Cap)

stock-summary
P/E

29.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.22

stock-summary
Return on Equity

12.39%

stock-summary
Price to Book

2.54